139 related articles for article (PubMed ID: 32028599)
1. Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1.
Wang C; Hamacher A; Petzsch P; Köhrer K; Niegisch G; Hoffmann MJ; Schulz WA; Kassack MU
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32028599
[TBL] [Abstract][Full Text] [Related]
2. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer In vitro.
Abou Najem S; Khawaja G; Hodroj MH; Rizk S
Curr Mol Pharmacol; 2019; 12(4):281-300. PubMed ID: 30868973
[TBL] [Abstract][Full Text] [Related]
4. Decitabine exerted synergistic effects with oxaliplatin in colorectal cancer cells with intrinsic resistance to decitabine.
Hosokawa M; Tanaka S; Ueda K; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2019 Jan; 509(1):249-254. PubMed ID: 30581001
[TBL] [Abstract][Full Text] [Related]
5. Emetine dihydrochloride: a novel therapy for bladder cancer.
Foreman KE; Jesse JN; Kuo PC; Gupta GN
J Urol; 2014 Feb; 191(2):502-9. PubMed ID: 24045224
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer.
Ryu H; Jin H; Ho JN; Bae J; Lee E; Lee SE; Lee S
Biol Pharm Bull; 2019; 42(1):66-72. PubMed ID: 30606990
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment.
Thy S; Hommel A; Meneceur S; Bartkowiak AL; Schulz WA; Niegisch G; Hoffmann MJ
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33803654
[TBL] [Abstract][Full Text] [Related]
8. Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer.
Li DR; Zhang H; Peek E; Wang S; Du L; Li G; Chin AI
J Urol; 2015 Aug; 194(2):547-55. PubMed ID: 25748177
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells.
Kim HJ; Gong MK; Yoon CY; Kang J; Yun M; Cho NH; Rha SY; Choi YD
Yonsei Med J; 2020 Jul; 61(7):587-596. PubMed ID: 32608202
[TBL] [Abstract][Full Text] [Related]
10. Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1.
Mpakou V; Spathis A; Bouhla A; Mpazani E; Papageorgiou S; Gkontopoulos K; Glezou E; Thomopoulos T; Foukas P; Pappa V
Exp Ther Med; 2021 Mar; 21(3):195. PubMed ID: 33488804
[TBL] [Abstract][Full Text] [Related]
11. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.
Ho IL; Kuo KL; Liu SH; Chang HC; Hsieh JT; Wu JT; Chiang CK; Lin WC; Tsai YC; Chou CT; Hsu CH; Pu YS; Shi CS; Huang KH
Sci Rep; 2015 Nov; 5():16948. PubMed ID: 26592553
[TBL] [Abstract][Full Text] [Related]
12. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin.
Shang D; Liu Y; Matsui Y; Ito N; Nishiyama H; Kamoto T; Ogawa O
Urology; 2008 Jun; 71(6):1220-5. PubMed ID: 18538698
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
14. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
[TBL] [Abstract][Full Text] [Related]
15. Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wild-type urothelial cancer cells through p38 activation.
Matsui Y; Watanabe J; Ding S; Nishizawa K; Kajita Y; Ichioka K; Saito R; Kobayashi T; Ogawa O; Nishiyama H
BJU Int; 2010 Feb; 105(4):558-64. PubMed ID: 19583730
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis of bladder cancer by sodium butyrate and cisplatin.
Maruyama T; Yamamoto S; Qiu J; Ueda Y; Suzuki T; Nojima M; Shima H
J Infect Chemother; 2012 Jun; 18(3):288-95. PubMed ID: 22041988
[TBL] [Abstract][Full Text] [Related]
17. DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer.
Mutze K; Langer R; Schumacher F; Becker K; Ott K; Novotny A; Hapfelmeier A; Höfler H; Keller G
Eur J Cancer; 2011 Aug; 47(12):1817-25. PubMed ID: 21458988
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line.
Yoon CY; Park MJ; Lee JS; Lee SC; Oh JJ; Park H; Chung CW; Abdullajanov MM; Jeong SJ; Hong SK; Byun SS; Lee ES; Lee SE
J Urol; 2011 Mar; 185(3):1102-11. PubMed ID: 21255805
[TBL] [Abstract][Full Text] [Related]
19. A combination of low-dose decitabine and chidamide resulted in synergistic effects on the proliferation and apoptosis of human myeloid leukemia cell lines.
Xu F; Guo H; Shi M; Liu S; Wei M; Sun K; Chen Y
Am J Transl Res; 2019; 11(12):7644-7655. PubMed ID: 31934307
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumor effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells.
Ho JN; Byun SS; Lee S; Oh JJ; Hong SK; Lee SE; Yeon JS
J Urol; 2015 Mar; 193(3):1016-22. PubMed ID: 25229559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
